Welcome to our dedicated page for UNITED THERAPEUTICS SEC filings (Ticker: UTHR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
United Therapeutics Corporation filings document an operating biotechnology company with Nasdaq-listed common stock and a public benefit corporation structure. Recent 8-K reports cover quarterly and annual operating results, business updates, clinical-study announcements for Tyvaso and ralinepag, and capital actions such as share repurchase programs and accelerated share repurchase agreements.
Proxy materials describe board elections, director changes, executive compensation, shareholder voting matters and governance practices. The company’s formal disclosures also address its treprostinil-centered pulmonary arterial hypertension business, development programs in pulmonary and transplant-related medicine, and common-stock capital structure.
UNITED THERAPEUTICS Corp (UTHR) entered into an accelerated share repurchase (ASR) agreement with Citibank, N.A. to repurchase approximately $477.6 million of its common stock, using the remaining portion of its previously announced $2.0 billion share repurchase authorization.
Under the ASR, the company will make an upfront payment of about $477.6 million around September 10, 2026 and receive an initial delivery of approximately 719,376 shares, representing about 75% of the total shares anticipated to be repurchased based on the September 8, 2026 closing price. The final number of shares will be determined using the average daily volume-weighted average price of UTHR common stock during the ASR term, less a discount and subject to customary adjustments.
The ASR is expected to be finally settled in the fourth quarter of 2026, at which time United Therapeutics may receive additional shares or, in limited circumstances, make a cash or share payment to Citi. As of September 4, 2026, United Therapeutics had approximately 42.9 million shares outstanding, and upon completion of this additional repurchase the company states it will have returned $4.0 billion to shareholders over approximately 2.5 years.
UNITED THERAPEUTICS Corp (UTHR) reported that Chairperson & CEO Martine Rothblatt, through a family trust, exercised 9,500 stock options on September 4, 2026 at an exercise price of $117.76 per share and received 9,500 shares of common stock. The trust then sold 9,500 common shares the same day in multiple open-market transactions at weighted average prices between roughly $485 and $492 per share under a pre-arranged Rule 10b5-1 trading plan adopted November 7, 2025. Following the option exercise, the family trust continues to hold 489,910 stock options expiring March 15, 2027, and Rothblatt also has 40,513 common shares held directly and 166 shares held indirectly by a spouse.
UNITED THERAPEUTICS Corp (UTHR) reported that Chairperson & CEO Martine A. Rothblatt, through family trusts, exercised stock options for 9,500 shares of common stock on September 3, 2026, at strike prices of $135.42 and $117.76 per share and sold 9,500 shares in multiple trades at prices ranging from about $478.44 to $491.55. These transactions were made pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which may continue until the earlier of the exercise of 1,734,410 stock options expiring March 15, 2027, or December 31, 2026. Following these transactions, Rothblatt is reported as holding 40,513 shares directly and 166 shares indirectly through a spouse, with additional holdings and options in family trusts where she and/or her spouse share investment power.
UNITED THERAPEUTICS Corp (UTHR) executive Paul A. Mahon, EVP & General Counsel, reported exercising stock options for 8,300 shares of common stock on September 3, 2026 at an exercise price of $146.03 per share and selling the resulting 8,300 shares in a series of trades on the same date. The filing states these option exercises and share sales were made pursuant to a pre-arranged Rule 10b5-1 trading plan entered into on August 11, 2025. Following the exercise, Mahon continues to hold 55,840 stock options directly.
UNITED THERAPEUTICS Corp (UTHR) disclosed that family trusts associated with Chairperson & CEO Martine A. Rothblatt exercised 9,500 stock options at an exercise price of $135.42 per share on September 2, 2026, acquiring 9,500 common shares indirectly and selling 9,500 common shares in multiple transactions around $478–$510 per share.
The option exercise and related sales were made pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. After this exercise, the relevant family trust held 8,910 stock options, while Rothblatt also held 40,513 common shares directly and 166 shares indirectly through a spouse.
UNITED THERAPEUTICS CORPORATION (UTHR) received a notice that officer Paul Mahon intends to sell up to 8,300 shares of common stock under Rule 144 through Morgan Stanley Smith Barney LLC. The planned sale has an aggregate market value of $4,000,836.55 and relates to shares acquired via a stock option exercise on September 3, 2026.
The notice states that 42,890,692 shares of United Therapeutics common stock are outstanding, and lists several prior Rule 144 sales by Mahon over the past three months, each involving 8,300 shares on various dates in June, July, and August 2026.
For UNITED THERAPEUTICS Corp (UTHR), Chairperson & CEO Martine A. Rothblatt reported an exercise of 9,500 stock options at an exercise price of $135.42 per share on September 1, 2026, held indirectly through a family trust. The options converted into 9,500 shares of common stock, which were then sold indirectly by the trust in a series of open-market transactions totaling 9,500 shares at weighted average prices ranging from about $510.43 to $516.57 per share. After the option exercise, the trust reported holding 18,410 stock options of the same series. The filing also lists 40,513 shares of common stock held directly, and 166 shares held indirectly by a spouse. All option exercises and related sales were made pursuant to a Rule 10b5-1 trading plan adopted on November 7, 2025, which continues until the earlier of the exercise of 1,734,410 options expiring March 15, 2027, or December 31, 2026.
UNITED THERAPEUTICS CORPORATION (UTHR) received a Rule 144 notice covering a proposed sale of 199,500 common shares for the account of officer Martine Rothblatt, through Morgan Stanley Smith Barney LLC, with the shares to be issued on 09/01/2026 upon the exercise of stock options for cash. The securities information section lists an aggregate market value of 101,820,810.00 and number of shares outstanding of 42,890,692 as of 09/01/2026. The filing also lists numerous prior 10b5-1 sales of 9,500-share blocks of common stock between 06/02/2026 and 08/31/2026, with corresponding transaction values disclosed for each date. Remarks state that shares are sold by Martine Rothblatt and/or the Martine Rothblatt Property Management Trust, which is beneficially owned by her.
UNITED THERAPEUTICS Corp (UTHR) reports that Chairperson & CEO Martine A. Rothblatt, through family trusts, exercised 9,500 stock options at an exercise price of $135.42 per share into 9,500 shares of common stock on August 31, 2026. The same day, those 9,500 shares were sold in multiple trades at weighted average prices around $508–$515 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. After this option exercise, a family trust holds 27,910 stock options, while Rothblatt also reports 40,513 shares of common stock held directly and 166 shares held indirectly by spouse.
UNITED THERAPEUTICS Corp (UTHR) reported that Chairperson & CEO Martine A. Rothblatt, through a family trust, exercised stock options for 9,500 shares of common stock at an exercise price of $135.42 per share on August 28, 2026. The resulting 9,500 shares of common stock were then sold in multiple open-market transactions at weighted-average prices generally between about $514 and $524 per share, each trade executed in multiple lots within specified price ranges. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which contemplates the potential exercise of up to 1,734,410 stock options expiring March 15, 2027, or earlier termination on December 31, 2026. Following these transactions, reported holdings include 40,513 shares of common stock held directly, 166 shares held indirectly by a spouse, and 37,410 stock options held in a family trust, with additional shares and options held through various family trusts where the reporting person and immediate family members are beneficiaries.